Quanterix Brand, Lucent Diagnostics, Introduces LucentAD Complete To Hep Detect Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Lucent Diagnostics, a brand under Quanterix, has introduced LucentAD Complete, a test that enhances Alzheimer's disease detection by improving on single biomarker tests. This advancement reduces the intermediate zone, allowing for more comprehensive results for patients.
October 28, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quanterix's brand, Lucent Diagnostics, has launched LucentAD Complete, a new test for Alzheimer's disease that improves detection by reducing the intermediate zone in biomarker tests.
The launch of LucentAD Complete by Lucent Diagnostics, a brand under Quanterix, represents a significant product development in Alzheimer's disease detection. This advancement is likely to positively impact Quanterix's stock as it enhances their product offerings and market position in the biotech sector.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80